Company Market News

Takeda Pharmaceutical Co. Ltd. (NYSE: TAK)
9:00 PM UTC, 12/12/25
Last: $14.33 Change: -0.06 %Change: -0.42% Volume: 2,123,444
Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus

Back

Last updated: 03/27/2025 9:39:49 AM

09:39 AM EDT, 03/27/2025 (MT Newswires) -- Mirum Pharmaceuticals (MIRM) said Thursday that its partner Takeda Pharmaceutical (TAK) has received clearance by Japan's Ministry of Health, Labour, and Welfare for Livmarli oral solution to treat cholestatic pruritus in people with Alagille syndrome and progressive familial intrahepatic cholestasis.

Mirum said the company and Takeda signed an exclusive licensing deal in September 2021 for the development and commercialization of Livmarli for rare cholestatic pediatric liver diseases in Japan.

Under the terms of the deal, Mirum is eligible to get a percentage of Takeda's annual net sales, the company said.

http://www.mtnewswires.com
Copyright © 2025 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.




Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2021 Wall Street Horizon, Inc.